Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) announced its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.42), Briefing.com reports. Supernus Pharmaceuticals had a return on equity of 2.83% and a net margin of 4.20%. The business had […]

Leave a Reply

Your email address will not be published.

Previous post Verve Therapeutics (NASDAQ:VERV) Announces Earnings Results
Next post Natwest clears former chief Alison Rose of misconduct in Farage debanking row